Through its large network of ambulatory labs, the university's pathology and lab medicine department is evaluating a BioFire rapid diagnostic test for the flu. 

Qiagen believes the flexibility of the Stat-Dx platform for an evolving reimbursement landscape will set it apart from other similar commercial platforms.

The Inhale project is assessing respiratory disease tests on Oxford Nanopore's MinIon and PCR platforms from Curetis and BioMérieux's BioFire Diagnostics.

BioMérieux said that the FilmArray RP2 reduces sample-to-result time to 45 minutes from about one hour, and provides increased pathogen coverage and sensitivity.

Applied Biocode intends to have panel for identifying 18 gastrointestinal pathogens on the clinical market by the end of the year.

Companies with diverse infectious disease diagnostic technology offerings said that molecular methods are complementary to, not competitive with traditional diagnostics.

The firm's GI panel has also been recently evaluated in pediatric populations, demonstrating a marked increase in overall pathogen detection.

The firm also reported a 46 percent increase in molecular biology sales due to growth in its FilmArray line.

The test detects 11 viruses and three bacterial pathogens in approximately one hour and requires two minutes of hands-on time. 

The study involved 11 sites and 1,560 prospectively collected patient samples and demonstrated high overall positive and negative percent agreement with comparator assays.


An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.